Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 22nd May 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 3, 2009
Previous Article Next Article

Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem

Author affiliations

Abstract

Covering: up to 2008

Ecteinascidins are marine natural products consisting of two or three linked tetrahydroisoquinoline subunits and an active carbinolamine functional group. Their potent antiproliferative activity against a variety of tumor cells makes them attractive candidates for development as anticancer agents. The lead compound, Yondelis® (trabectedin, ET-743) is the first marine anticancer agent approved in the European Union for patients with soft tissue sarcoma (STS). Positive results of a large randomized Phase III clinical trial in ovarian cancer have recently been presented. The low amounts present in its natural source, the tunicate Ecteinascidia turbinata, made it necessary to develop efficient synthetic procedures. The original total synthesis is reviewed as well as a new semisynthetic process from the readily available cyanosafracin B, which has solved the supply problem.

Graphical abstract: Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem

Back to tab navigation

Publication details

The article was received on 30 Sep 2008 and first published on 07 Jan 2009


Article type: Review Article
DOI: 10.1039/B808331M
Nat. Prod. Rep., 2009,26, 322-337

  •   Request permissions

    Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem

    C. Cuevas and A. Francesch, Nat. Prod. Rep., 2009, 26, 322
    DOI: 10.1039/B808331M

Search articles by author

Spotlight

Advertisements